|
Investigating the effect of estrogen-based nanoparticles on diffuse traumatic brain injuries in male rats
|
Sedigheh Amiresmaili   , Mohammad Khaksari , Ghasem Sargazi |
|
|
|
Abstract: (259 Views) |
Introduction: The neuroprotective effects of estrogen in the treatment of traumatic brain injury (TBI) are well known. However, there are safety concerns regarding the use of high and chronic doses of estrogen, so it has limited clinical use. The neuroprotective benefits of nanoparticles as a therapeutic intervention in patients with neurological diseases have been researched recently. In the current study, low doses of estrogen using nanoparticles were studied in the treatment of brain injury.
Methods and Materials: Diffuse TBI caused by the Marmarou model in male rats. In this experimental study, 42 male Wistar rats, weighing 200-250 grams, were used and the animals were randomly divided into 6 groups, with 7 rats in each group including: Sham, TBI, vehicle (DMSO 1%), and three different doses of nanoestradiol including: the low dose (2.5 µg/kg), the middle dose (5 µg/kg), and the high dose (10 µg/kg). Drugs were injected intraperitoneally (ip) 30 minute after TBI.
Results: The results showed that TBI causes an increase in brain edema, oxidant biomarkers (MDA and NO) and a decrease in VCS and antioxidant factors (GPX and SOD). Also, nanoestradiol exerts a dose-dependent neuroprotective effect, so that dose 10 µg/kg shows better protective effects than nanoestradiol other doses.
Conclusion: The results of the experiments showed that nanoestradiol as an antioxidant is capable of sweeping species Reactive oxygen (ROS) caused by traumatic brain injury and as a result improves its complications such as brain edema and VCS. Also, with increasing the drug dose, the amount of brain edema, VCS, and oxidative stress factors significantly improved.
|
|
| Keywords: Traumatic brain injury, Nanoestradiol, Oxidative stress |
|
|
Full-Text [PDF 255 kb]
(37 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2023/12/17 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
